Salah-Eddine Lamhamedi-Cherradi1, Brian A Menegaz1, Vandhana Ramamoorthy1, Deeksha Vishwamitra1, Ying Wang1, Rebecca L Maywald1, Adriana S Buford1, Izabela Fokt1, Stanislaw Skora1, Jing Wang1, Aung Naing1, Alexander J Lazar1, Eric M Rohren1, Najat C Daw1, Vivek Subbiah1, Robert S Benjamin1, Ravin Ratan1, Waldemar Priebe1, Antonios G Mikos1, Hesham M Amin1, Joseph A Ludwig2. 1. Departments of Sarcoma Medical Oncology (SELC, BAM, VR, RSB, RR, JAL), Hematopathology (DV, HMA), Bioinformatics and Computational Biology (YW, JW), Investigational Cancer Therapeutics (AN, VS), Pediatrics-Patient Care (NCD), Experimental Therapeutics (IF, SS, WP), and Pathology (AJL), The University of Texas MD Anderson Cancer Center, Houston, TX; Departments of Radiology (EMR) and Molecular & Human Genetics (RLM), Baylor College of Medicine, Houston, TX; Department of Pediatric-Oncology, Texas Children's Hospital. Houston, TX (ASB); Departments of Chemical and Biomolecular Engineering and Bioengineering, Rice University, Houston, TX (AGM). 2. Departments of Sarcoma Medical Oncology (SELC, BAM, VR, RSB, RR, JAL), Hematopathology (DV, HMA), Bioinformatics and Computational Biology (YW, JW), Investigational Cancer Therapeutics (AN, VS), Pediatrics-Patient Care (NCD), Experimental Therapeutics (IF, SS, WP), and Pathology (AJL), The University of Texas MD Anderson Cancer Center, Houston, TX; Departments of Radiology (EMR) and Molecular & Human Genetics (RLM), Baylor College of Medicine, Houston, TX; Department of Pediatric-Oncology, Texas Children's Hospital. Houston, TX (ASB); Departments of Chemical and Biomolecular Engineering and Bioengineering, Rice University, Houston, TX (AGM) jaludwig@mdanderson.org.
Abstract
BACKGROUND: Therapies cotargeting insulin-like growth factor receptor 1 (IGF-1R) and mammalian target of rapamycin (mTOR) have demonstrated remarkable, albeit short-lived, clinical responses in a subset of Ewing sarcoma (ES) patients. However, the mechanisms of resistance and applicable strategies for overcoming drug resistance to the IGF-1R/mTOR blockade are still undefined. METHODS: To elucidate predominant mechanism(s) of acquired drug resistance while identifying synergistic drug combinations that improve clinical efficacy, we generated more than 18 ES cell lines resistant to IGF-1R- or mTOR-targeted therapy. Two small-molecule inhibitors of IGF-1R were chosen, NVP-ADW-742 (IGF-1R-selective) and OSI-906 (a dual IGF-1R/insulin receptor alpha [IR-α] inhibitor). Reverse-phase protein lysate arrays (RPPAs) revealed proteomic changes linked to IGF-1R/mTOR resistance, and selected proteins were validated in cell-based assays, xenografts, and within human clinical samples. All statistical tests were two-sided. RESULTS: Novel mechanisms of resistance (MOR) emerged after dalotuzumab-, NVP-ADW-742-, and OSI-906-based targeting of IGF-1R. MOR to dalotuzumab included upregulation of IRS1, PI3K, and STAT3, as well as p38 MAPK, which was also induced by OSI-906. pEIF4E(Ser209), a key regulator of Cap-dependent translation, was induced in ridaforolimus-resistant ES cell lines. Unique drug combinations targeting IGF-1R and PI3K-alpha or Mnk and mTOR were synergistic in vivo and vitro (P < .001) as assessed respectively by Mantel-Cox and isobologram testing. CONCLUSIONS: We discovered new druggable targets expressed by chemoresistant ES cells, xenografts, and relapsed human tumors. Joint suppression of these newfound targets, in concert with IGF-1R or mTOR blockade, should improve clinical outcomes.
BACKGROUND: Therapies cotargeting insulin-like growth factor receptor 1 (IGF-1R) and mammalian target of rapamycin (mTOR) have demonstrated remarkable, albeit short-lived, clinical responses in a subset of Ewing sarcoma (ES) patients. However, the mechanisms of resistance and applicable strategies for overcoming drug resistance to the IGF-1R/mTOR blockade are still undefined. METHODS: To elucidate predominant mechanism(s) of acquired drug resistance while identifying synergistic drug combinations that improve clinical efficacy, we generated more than 18 ES cell lines resistant to IGF-1R- or mTOR-targeted therapy. Two small-molecule inhibitors of IGF-1R were chosen, NVP-ADW-742 (IGF-1R-selective) and OSI-906 (a dual IGF-1R/insulin receptor alpha [IR-α] inhibitor). Reverse-phase protein lysate arrays (RPPAs) revealed proteomic changes linked to IGF-1R/mTOR resistance, and selected proteins were validated in cell-based assays, xenografts, and within humanclinical samples. All statistical tests were two-sided. RESULTS: Novel mechanisms of resistance (MOR) emerged after dalotuzumab-, NVP-ADW-742-, and OSI-906-based targeting of IGF-1R. MOR to dalotuzumab included upregulation of IRS1, PI3K, and STAT3, as well as p38 MAPK, which was also induced by OSI-906. pEIF4E(Ser209), a key regulator of Cap-dependent translation, was induced in ridaforolimus-resistant ES cell lines. Unique drug combinations targeting IGF-1R and PI3K-alpha or Mnk and mTOR were synergistic in vivo and vitro (P < .001) as assessed respectively by Mantel-Cox and isobologram testing. CONCLUSIONS: We discovered new druggable targets expressed by chemoresistant ES cells, xenografts, and relapsed humantumors. Joint suppression of these newfound targets, in concert with IGF-1R or mTOR blockade, should improve clinical outcomes.
Authors: Razelle Kurzrock; Amita Patnaik; Joseph Aisner; Terri Warren; Stephen Leong; Robert Benjamin; S Gail Eckhardt; Joseph E Eid; Gerard Greig; Kai Habben; Cinara D McCarthy; Lia Gore Journal: Clin Cancer Res Date: 2010-04-06 Impact factor: 12.531
Authors: Salah-Eddine Lamhamedi-Cherradi; Brian A Menegaz; Vandhana Ramamoorthy; Ramani A Aiyer; Rebecca L Maywald; Adrianna S Buford; Dannette K Doolittle; Kirk S Culotta; James E O'Dorisio; Joseph A Ludwig Journal: Mol Cancer Ther Date: 2015-05-11 Impact factor: 6.261
Authors: Alberto S Pappo; Shreyaskumar R Patel; John Crowley; Denise K Reinke; Klaus-Peter Kuenkele; Sant P Chawla; Guy C Toner; Robert G Maki; Paul A Meyers; Rashmi Chugh; Kristen N Ganjoo; Scott M Schuetze; Heribert Juergens; Michael G Leahy; Birgit Geoerger; Robert S Benjamin; Lee J Helman; Laurence H Baker Journal: J Clin Oncol Date: 2011-10-24 Impact factor: 44.544
Authors: Jin Gao; Jon W Chesebrough; Susan A Cartlidge; Sally-Ann Ricketts; Leonard Incognito; Margaret Veldman-Jones; David C Blakey; Mohammad Tabrizi; Bahija Jallal; Pamela A Trail; Steven Coats; Klaus Bosslet; Yong S Chang Journal: Cancer Res Date: 2011-01-18 Impact factor: 12.701
Authors: Marco Santoro; Brian A Menegaz; Salah-Eddine Lamhamedi-Cherradi; Eric R Molina; Danielle Wu; Waldemar Priebe; Joseph A Ludwig; Antonios G Mikos Journal: Tissue Eng Part A Date: 2017-01 Impact factor: 3.845
Authors: Sabine Heitzeneder; Elena Sotillo; Jack F Shern; Sivasish Sindiri; Peng Xu; Robert Jones; Michael Pollak; Pernille R Noer; Julie Lorette; Ladan Fazli; Anya Alag; Paul Meltzer; Ching Lau; Cheryl A Conover; Claus Oxvig; Poul H Sorensen; John M Maris; Javed Khan; Crystal L Mackall Journal: J Natl Cancer Inst Date: 2019-09-01 Impact factor: 13.506
Authors: Eric R Molina; Letitia K Chim; Sergio Barrios; Joseph A Ludwig; Antonios G Mikos Journal: Tissue Eng Part B Rev Date: 2020-02-14 Impact factor: 6.389
Authors: Eric R Molina; Letitia K Chim; Maria C Salazar; Shail M Mehta; Brian A Menegaz; Salah-Eddine Lamhamedi-Cherradi; Tejus Satish; Sana Mohiuddin; David McCall; Ana Maria Zaske; Branko Cuglievan; Alexander J Lazar; David W Scott; Jane K Grande-Allen; Joseph A Ludwig; Antonios G Mikos Journal: Acta Biomater Date: 2019-09-19 Impact factor: 8.947
Authors: Yongxin Chen; Filemon Dela Cruz; Romeil Sandhu; Andrew L Kung; Prabhjot Mundi; Joseph O Deasy; Allen Tannenbaum Journal: Sci Rep Date: 2017-08-01 Impact factor: 4.379